1. Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre study
- Author
-
Gianluca Esposito, Maria Cazzato, Maria Rinzivillo, Emanuela Pilozzi, Edith Lahner, Bruno Annibale, and Francesco Panzuto
- Subjects
gastroscopy ,Endoscopic Mucosal Resection ,Hepatology ,Gastroenterology ,Colonic Polyps ,carcinoids ,Colonoscopy ,atrophic gastritis ,neuroendocrine tumours ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,Treatment Outcome ,Gastric Mucosa ,Stomach Neoplasms ,Intestinal Neoplasms ,Humans ,Prospective Studies ,Neoplasm Recurrence, Local ,Retrospective Studies - Abstract
This study aimed to evaluate the outcome of patients with type 1 gastric neuroendocrine neoplasia (T1gNENs) treated with different endoscopic approaches.Patients were managed with endoscopic surveillance at regular intervals. Resection was performed by forceps or cold snare in tumours10 mm, otherwise mucosal resection (EMR) or submucosal dissection (ESD) were done.127 T1gNENs, detected in 80 patients, were included. 87.4% of them were5 mm, whereas 8.7% were 6-10 mm, 3.1% were 11-20 mm, and 0.8% was20 mm. Ki673%% was found in 85.8% tumours, whereas it was 3%-20% in the remaining 14.2% lesions. Noninterventional management (surveillance without radical resection) was performed in 15 patients (18.7%) with T1gNENs5 mm. None of them underwent disease progression during follow-up. among the 65 patients treated by radical endoscopic resection, 37 patients (56.9%) had disease recurrence. 48.5% T1gNENs were removed by forceps, 16.8% by cold snare, 31.7% by EMR and 3% by ESD. The recurrence rate was similar among the different endoscopic techniques used.The management of T1gNENs may be planned based on tumour size. T1gNENs5 mm for which the initial removal is not radical could be followed up by noninterventional endoscopic surveillance.
- Published
- 2022